In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average target of $3.83, a high estimate of $6.00, and a low estimate of $1.00. This ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Arkansas-based Lexicon Inc. and its divisions have earned five safety awards from the American Institute of Steel ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 13.42%, which has investors questioning if this is right time ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy LX9851.

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 25.32%, which has investors questioning if this is right time to buy.

(Reuters) -Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen ...

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) climbed ~95% in the premarket trading on Friday after the Texas-based biotech announced an exclusive license agreement with Novo Nordisk (NVO) ...

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...

The company, Lexicon, says they expect the expansion to bring 60 new jobs to the region. Company officials say the expansion is set to take place over two years. They plan to add 5,000 square feet ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...